Please assess the completion status of the following clinical trial:

Trial Title: Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals aged 18 or over, regardless of gender;~2. Patients hospitalized in moderate to severe stages in line with the Ministry of Health classification;~3. Positive diagnosis for SARS-CoV-2 by molecular amplification of the virus in RT-PCR diagnosed from a respiratory sample (nasopharynx, oropharyngeal, lower respiratory tract \[eg, sputum\]) collected \<96 hours before randomization;~4. Time of onset of symptoms and inclusion ≤ 14 days;~5. Internation within 48 hours after inclusion in the study;~6. Follow-up availability during the study period;~7. Voluntary membership to participate in the study and signing the Informed Consent Form.~Exclusion Criteria:~1. Patients known or suspected of being sensitive to AZVUDINE or excipients (inactive ingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone K30, croscarmellose sodium, magnesium stearate);~2. Patients diagnosed with pneumonia caused by other pathogens;~3. Patients with liver disease (total bilirubin ≥2 times above the normal limit, ALT / TGP and AST / TGO ≥5 times above the normal limit)~4. Patients with renal failure (glomerular filtration rate ≤60mL / min / 1.73 m2) or are receiving continuous renal replacement therapy, hemodialysis or peritoneal dialysis;~5. Individuals with malabsorption syndrome, or other conditions that affect gastrointestinal absorption, and circumstances in which patients need intravenous nutrition, or cannot take drugs orally or nasogastrically;~6. Pregnant or lactating women, or women with the potential to become pregnant during the study period and within 6 months after the end of administration;~7. Patients already included in other clinical trials;~8. Patient under treatment for HIV;~9. Patients being treated with other antivirals (eg lopinavir / ritonavir, remdesivir, umifenovir / arbidol, favipiravir, interferon-α)~10. Patients undergoing treatment with monoclonal antibodies (eg tocilizumab and sarilumab / kevzara);~11. Patients who are on a clinical treatment plan that includes the concomitant administration of any other experimental treatment or off-label use of drugs already on the market (eg hydroxychloroquine sulfate;~12. Patients who require invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at the time of randomization;~13. Any clinically significant medical condition or medical history that, in the investigator's opinion, might discourage participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm AZVUDINE (Type: EXPERIMENTAL): Experimental:~AZVUDINE 1mg tablet,~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment for up to 14 days
- Arm Placebo (Type: PLACEBO_COMPARATOR): Control:~AZVUDINE placebo,~Interventions:~AZVUDINE placebo, 5 tablets QD + standard treatment for up to 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).